Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Moderna

Novavax

Pfizer

Two experimental coronavirus vaccines, manufactured jointly by Pfizer and BioNTech, have received fast track status from the FDA.

Race to Coronavirus Vaccine Heats Up: 5 Stocks in Spotlight

A senior functionary of President DonaldTrump’s administration has disclosed that health officials and drugmakers in the United States are expecting the production of a COVID-19 vaccine to begin by the end of summer.

Trump Administration Expects Coronavirus Vaccine Production To Start By The End Of Summer

Abbott Labs

Eli Lilly

Merck

Large drugmakers are hoping to stop a looming global crisis that could be much worse than COVID-19.

Why Big Pharma's $1 Billion Bet to Prevent a Bacterial Pandemic Matters for You

Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports second-quarter results.

J&J (JNJ) to Kickstart Q2 Earnings for the Pharma Sector

Delta Air Lines

Netflix

PepsiCo

Domino's Pizza

UnitedHealth Group

A new earnings reporting season kicks off this week. Although coronavirus concerns have been minimized as the broad markets have stabilized, there still will be an impact on these reports.

Delta Air, Johnson & Johnson, Netflix, Pepsi and More Major Earnings This Week

Aflac

Cisco Systems

Con Ed

Tyson Foods

Unilever

Walgreens

Dividend Stock Purchase: Lanny's June 2020 Summary

AstraZeneca

AstraZeneca, Johnson & Johnson, Merck, and Pfizer will also field questions from lawmakers.

Moderna and Other Coronavirus Vaccine Developers to Testify in Congress July 21

Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?

Bellwether health care stocks Johnson & Johnson and Abbott Laboratories are widely expected to report earnings crashes next Thursday and declining sales amid the coronavirus pandemic.
The post Health Giant Johnson & Johnson On Deck To Report — Here's What We Know appeared first on Investor's Business Daily.

Health Giant Johnson & Johnson On Deck To Report — Here's What We Know

More than 170 nonprofit groups on Wednesday called for Johnson & Johnson to stop selling its talc-based Johnson’s Baby Powder world-wide, citing concerns that it contains cancer-causing asbestos, according to a statement from advocacy group Black Women for Wellness.

Nonprofits urge Johnson & Johnson to halt sales of Baby Powder globally

Johnson & Johnson's Cilag Holding will offer up to approximately 11.8 million existing ordinary shares in Idorsia Ltd in an accelerated bookbuilding to commence on Wednesday, the transaction's bookrunner said.

J&J's Cilag to sell up to 11.8 million Idorsia shares

Johnson & Johnson: Excellent Company Tarnished By Scandal

Inovio Pharmaceuticals

Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp speed.”

Is There a Coronavirus Vaccine Yet?

In the latest trading session, Johnson & Johnson (JNJ) closed at $142.85, marking a -0.09% move from the previous day.

Johnson & Johnson (JNJ) Stock Moves -0.09%: What You Should Know

Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.

Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine

Johnson & Johnson: Building Your Core

GENEVA, July 6, 2020 /PRNewswire/ -- The Stop TB Partnership and Johnson & Johnson (NYSE: JNJ) – with support from the Global Fund to Fight AIDS, TB and Malaria, and the U.S. Agency for International Development (USAID) – today announced joint efforts to help enable low- and middle-income...

Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries

Johnson & Johnson said on Monday it was slashing the price of its version of the tuberculosis drug bedaquiline to $340 from its original price of $400, for a six-month treatment, in low- and middle-income countries, to scale up its use during the COVID-19 pandemic.

Johnson & Johnson cuts price of TB drug bedaquiline in poorer countries

Brixmor Property Group

EPR Properties

Federal Realty Investment Trust

Spirit Realty Capital

STORE Capital

VEREIT

REITs Are Doomed - Not

Emergent BioSolutions

Shares of Emergent BioSolutions Inc. EBS, +2.64% were up 1.1% in premarket trading on Monday after it announced a five-year deal with Johnson & Johnson JNJ, +0.42% to manufacture the drug substance for the drugmaker's still-investigational COVID-19 vaccine.

Emergent BioSolutions inks coronavirus vaccine manufacturing deal with J&J

Emergent BioSolutions Inc said on Monday it has signed a five-year pact to make the drug substance used in Johnson & Johnson's COVID-19 vaccine candidate, in a deal valued at about $480 million for the first two years.

Emergent to make drug substance for J&J's COVID-19 vaccine candidate

Automatic Data Processing

Bank of America

Enterprise Products Partners

General Dynamics

Prudential Financial

Toronto-Dominion Bank

ViacomCBS

This article is part of our monthly series, where we highlight five companies that are large cap, relatively safe, dividend paying, and are offering large discounts to their historical norms.

5 Safe And Cheap Dividend Stocks To Invest In (July 2020)

J&J (JNJ) gets approval from the European Commission for Ebola vaccine.

Johnson & Johnson Gets European Approval for Ebola Vaccine

Johnson & Johnson’s stock (NYSE: JNJ) has gained 27% since the March 23 lows, while Pfizer’s stock (NYSE: PFE) is up 16%, both underperforming the broader S&P, which is up 39%. The lockdown in various parts of the world has had a negative impact on the pharmaceuticals industry worldwide.

News for Johnson & Johnson Stock (JNJ)